Cinarizine - instructions for use, dose, side effects, contraindications

Composition for one tablet: active substance: cinnarizine (in terms of 100% substance) - 25 mg; excipients: lactose (milk sugar) - 102.35 mg, potato starch - 17.4905 mg, silicon colloidal dioxide (aerosil) - 0.1562 mg, povidone (low molecular weight polyvinylpyrrolidone medical) 3.5 mg, magnesium stearate 1.5033 mg .

Description:

Tablets white or white with a creamy shade of color, flat-cylindrical shape with a bevel.

Pharmacotherapeutic group:The blocker of "slow" calcium channels.

ATX: & nbsp

N.07.C.A.02 Cinnarizine

Pharmacodynamics:

Selective blocker slow calcium channels, reduces the entry of calcium ions into cells and reduces their content in the depot of the plasmolemma, lowers the tone of the smooth muscle arterioles.

Immediately affecting the smooth muscles of blood vessels, reduces their response to nutrients (adrenaline, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially with respect to cerebral vessels), without having a significant effect on blood pressure. It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Increases the elasticity of erythrocyte membranes, their ability to deform, reduces the viscosity of the blood. Increases muscle resistance to hypoxia.

Pharmacokinetics:

Absorbed in the stomach and intestines. The maximum concentration in the blood plasma after ingestion comes in 1-3 hours. The connection with plasma proteins is 91%. It is completely metabolized in the liver (via glucuronation). The half-life is 4 hours.It is excreted in the form of metabolites: 1/3 - kidneys and 2/3 - with fecal masses.

Indications:

symptoms of cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration of attention);
vestibular disorders (including Meniere's disease, dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinthine origin);
prevention of kinetosis ("road sickness" - sea and air sickness);
migraine (prevention of seizures);
violations of peripheral circulation: Raynaud's disease, "intermittent" lameness, acrocyanosis, trophic disorders (including trophic and varicose ulcers).

Contraindications:

Hypersensitivity, pregnancy, lactation, children under 5 years, lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.

Carefully:With caution in Parkinson's disease.

Dosing and Administration:

Inside, after eating.

With insufficiency of cerebral circulation: 25-50 mg three times a day.

If peripheral circulation is disturbed, 50-75 mg three times a day.

With vestibular disorders - 25 mg three times a day.

With kinetosis ("road" disease): adults - 25 mg for half an hour before the road. If necessary, repeated intake of 25 mg after 6 hours.

The dose for children from 5 years is 1/2 dose recommended by adults. The maximum recommended dose should not exceed 225 mg (9 tablets) per day.

The course of treatment is from several weeks to several months.

With high sensitivity to the drug, treatment starts with 1/2 dose, increasing it gradually.

Side effects:

From the nervous system: drowsiness, fatigue, headache, extrapyramidal disorders (tremor of limbs and increased muscle tone, hypokinesia), depression.

From the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice.

From the skin: increased sweating, red flat lichen (extremely rare).

Allergic reactions: skin rash.

Other: decrease in blood pressure, weight gain, development of lupus-like syndrome.

Overdose:

Symptoms: vomiting, drowsiness, tremor, excessive lowering of blood pressure, coma.

Treatment: there is no specific antidote, gastric lavage, Activated carbon, symptomatic therapy.

Interaction:

Strengthens the depressing effect on the central nervous system, alcohol, nootropic, sedative, hypotensive and vasodilating drugs. Reduces the effect of hypertensive medications.

Special instructions:

Patients with Parkinson's disease, the drug is prescribed only in cases when the benefits of cinnarizine treatment outweigh the possible worsening of the course of the underlying disease.

In connection with the antihistamine effect, the appointment of cinnarizine should be discontinued 4 days before the allergic skin test. Cinnarizine can affect the result in the anti-doping control of athletes (false positive result).

With prolonged use, it is recommended that a control laboratory examination of the liver, kidneys, and peripheral blood is recommended.

Effect on the ability to drive transp. cf. and fur:It is possible to develop drowsiness, especially at the beginning of treatment, therefore, care should be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased concentration and speed of psychomotor reactions.

Form release / dosage:

Tablets 25 mg.

Packaging:

10 tablets are placed in a contour mesh package.

5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N000776 / 01

Date of registration:23.03.2009

The owner of the registration certificate:MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia

Manufacturer: & nbsp

MOSHIMFARM PREPARATES them. NA Semashko OJSC Russia

Information update date: & nbsp09.10.2015

Illustrated instructions

Instructions

Cinnarizine (Cinnarizine)